Second-Generation Antimitotics in Cancer Clinical Trials

• Prif Awduron: Pedro Novais (Awdur), Patrícia M. A. Silva (Awdur), Isabel Amorim (Awdur), Hassan Bousbaa (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2021-07-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Mitosis represents a promising target to block cancer cell proliferation. Classical antimitotics, mainly microtubule-targeting agents (MTAs), such as taxanes and vinca alkaloids, are amongst the most successful anticancer drugs. By disrupting microtubules, they activate the spindle assembly checkpoi...